Welcome to our dedicated page for Moderna SEC filings (Ticker: MRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.
Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.
Reporting person: Shannon Thyme Klinger, Chief Legal Officer of Moderna, reported equity transactions in the issuer's common stock. The filing shows conversion of restricted stock units (RSUs) into common shares and contemporaneous share withholdings to satisfy tax obligations. Specifically, 774 RSUs converted into 774 shares on 08/27/2025 and 329 RSUs converted into 329 shares on 08/28/2025. On 08/27/2025 the reporting person had 28,257 shares after a 774-share conversion and a 375-share withholding; on 08/28/2025 the filing shows 28,051 shares after a 329-share conversion and a 160-share withholding. The RSU awards vest 25% at the initial vesting date with the remainder in twelve equal quarterly installments.
Stephen Hoge, President and director of Moderna, Inc. (MRNA), reported Section 16 transactions showing conversion of restricted stock units into common stock and related share withholding for taxes. On 08/27/2025, 1,437 RSUs converted into common stock and 695 shares were withheld at $24.73 to satisfy tax obligations, leaving 1,453,556 shares beneficially owned after that transaction. On 08/28/2025, 611 RSUs converted and 296 shares were withheld at $25.10, with total owned shares reported at 1,453,176. The report also discloses 4,116 shares held indirectly by Valhalla, LLC and 151,933 shares owned by a trust for the benefit of the reporting person’s spouse and children, of which the reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
Filing: Form 4 filed for Moderna, Inc. (MRNA) reporting the vesting and conversion of restricted stock units into common stock by Director David M. Rubenstein.
Key facts: On 08/05/2025 850 restricted stock units vested and converted one-for-one into 850 shares of common stock at a price of $0. Following the transaction, the reporting person beneficially owned 1,527 shares. The Form 4 was signed by attorney-in-fact James Dillon on 08/06/2025. The filing indicates a direct ownership form and uses transaction code M with no other transactions disclosed.